Following planned data collection, DURIPANC Primary Endpoint analysis is anticipated to begin in December 2026 and topline results are anticipated in Q1 2027. DURIPANC’s primary endpoint is Clinical ...

This indication is approved under accelerated approval based on reduction of proteinuria. It has not been established whether VOYXACT slows kidney function decline over the long-term in patients with ...

Extreme fatigue, a racing pulse, shortness of breath, brain fog, aching joints-the symptoms of long COVID can vary widely, ...

Bispecific antibodies, which bind to two targets, are sweeping into the clinic and are prompting even more elaborate versions ...

(Teerasak1988/iStock/Getty Images Plus) For decades, scientists have theorized that kids actually need to get a bit dirty for ...

Malaria parasites proliferate in an unusual way. Rather than dividing into two daughter cells like human cells, they first amplify their genetic material tenfold, hundredfold or even thousandfold ...

Clinical data from the HERCULES trial show that tolebrutinib reduces six-month confirmed disability progression by 31% in non ...

Chronic hepatitis B (CHB) remains a major global challenge. Current therapies suppress HBV but rarely achieve functional cure ...

First patients dosed at City of Hope and the University of Alabama at BirminghamDOC-RM recently featured as a ...

The gut mucosa is no longer viewed merely as a site of digestion and defense; it is now recognized as a central orchestrator ...

InnoCare Pharma announced Monday that its oral tyrosine kinase 2 (TYK2) inhibitor fadeucravacitinib met the primary endpoint ...

CHIMERA enrolls surgical candidates with stage I–IIIa epithelioid or biphasic pleural mesothelioma, aiming to optimize multimodality outcomes in a highly selected population. Treatment includes ...